U.S. markets open in 2 hours 19 minutes
  • S&P Futures

    4,171.25
    +17.75 (+0.43%)
     
  • Dow Futures

    33,347.00
    +192.00 (+0.58%)
     
  • Nasdaq Futures

    14,098.00
    +63.00 (+0.45%)
     
  • Russell 2000 Futures

    2,241.70
    +11.10 (+0.50%)
     
  • Crude Oil

    71.68
    +0.04 (+0.06%)
     
  • Gold

    1,782.60
    +13.60 (+0.77%)
     
  • Silver

    26.03
    +0.06 (+0.23%)
     
  • EUR/USD

    1.1901
    +0.0035 (+0.30%)
     
  • 10-Yr Bond

    1.4500
    0.0000 (0.00%)
     
  • Vix

    20.05
    +2.30 (+12.96%)
     
  • GBP/USD

    1.3876
    +0.0067 (+0.49%)
     
  • USD/JPY

    110.1190
    -0.0310 (-0.03%)
     
  • BTC-USD

    32,193.16
    -1,848.67 (-5.43%)
     
  • CMC Crypto 200

    790.34
    -149.61 (-15.92%)
     
  • FTSE 100

    7,029.56
    +12.09 (+0.17%)
     
  • Nikkei 225

    28,010.93
    -953.15 (-3.29%)
     

REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

ROCKVILLE, Md., April 28, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 5, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2021, and recent operational highlights.

To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 7044809. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com

Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

(PRNewsfoto/REGENXBIO Inc.)
(PRNewsfoto/REGENXBIO Inc.)
Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-may-5-to-discuss-first-quarter-2021-financial-results-and-recent-operational-highlights-301279354.html

SOURCE REGENXBIO Inc.